

Carmela Ricciardelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1156189/publications.pdf>

Version: 2024-02-01

85
papers

4,552
citations

101384

36
h-index

106150

65
g-index

87
all docs

87
docs citations

87
times ranked

7196
citing authors

#	ARTICLE	IF	CITATIONS
1	Androgen Receptor Inhibits Estrogen Receptor- α Activity and Is Prognostic in Breast Cancer. <i>Cancer Research</i> , 2009, 69, 6131-6140.	0.4	329
2	Chick Chorioallantoic Membrane (CAM) Assay as an In Vivo Model to Study the Effect of Newly Identified Molecules on Ovarian Cancer Invasion and Metastasis. <i>International Journal of Molecular Sciences</i> , 2012, 13, 9959-9970.	1.8	286
3	Androgens induce divergent proliferative responses in human breast cancer cell lines. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995, 52, 459-467.	1.2	226
4	The biological role and regulation of versican levels in cancer. <i>Cancer and Metastasis Reviews</i> , 2009, 28, 233-245.	2.7	201
5	The Role of Annexin A2 in Tumorigenesis and Cancer Progression. <i>Cancer Microenvironment</i> , 2011, 4, 199-208.	3.1	197
6	Global Levels of Specific Histone Modifications and an Epigenetic Gene Signature Predict Prostate Cancer Progression and Development. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2611-2622.	1.1	145
7	The role of ABC transporters in ovarian cancer progression and chemoresistance. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 220-256.	2.0	139
8	Glioma-derived versican promotes tumor expansion via glioma-associated microglial/macrophages Toll-like receptor 2 signaling. <i>Neuro-Oncology</i> , 2015, 17, 200-210.	0.6	131
9	A potential autocrine role for vascular endothelial growth factor in prostate cancer. <i>Cancer Research</i> , 2002, 62, 854-9.	0.4	131
10	Expression of Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and Hyaluronan, and Their Association with Disease Outcome in Node-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2004, 10, 2491-2498.	3.2	129
11	Formation of Hyaluronan- and Versican-rich Pericellular Matrix by Prostate Cancer Cells Promotes Cell Motility. <i>Journal of Biological Chemistry</i> , 2007, 282, 10814-10825.	1.6	126
12	Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. <i>Clinical Cancer Research</i> , 2002, 8, 1054-60.	3.2	120
13	Role of Versican, Hyaluronan and CD44 in Ovarian Cancer Metastasis. <i>International Journal of Molecular Sciences</i> , 2011, 12, 1009-1029.	1.8	107
14	Extracellular Matrix of Ovarian Tumors. <i>Seminars in Reproductive Medicine</i> , 2006, 24, 270-282.	0.5	105
15	Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non-organ confined disease. <i>Prostate</i> , 2005, 63, 19-28.	1.2	103
16	Transforming Growth Factor-Beta-Induced Protein (TGFBI)/ β ig-H3: A Matrix Protein with Dual Functions in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2012, 13, 10461-10477.	1.8	96
17	Control of Androgen Receptor Signaling in Prostate Cancer by the Cochaperone Small Glutamine-Rich Tetratricopeptide Repeat Containing Protein β . <i>Cancer Research</i> , 2007, 67, 10087-10096.	0.4	82
18	Epigenetic biomarkers in prostate cancer: Current and future uses. <i>Cancer Letters</i> , 2014, 342, 248-256.	3.2	78

#	ARTICLE	IF	CITATIONS
19	Androgen Receptor Signaling. <i>Cancer Research</i> , 2004, 64, 2619-2626.	0.4	74
20	Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer. <i>BMC Cancer</i> , 2013, 13, 476.	1.1	66
21	Transforming growth factor- β -induced protein secreted by peritoneal cells increases the metastatic potential of ovarian cancer cells. <i>International Journal of Cancer</i> , 2011, 128, 1570-1584.	2.3	65
22	Modulation of prostate cancer cell attachment to matrix by versican. <i>Cancer Research</i> , 2003, 63, 4786-91.	0.4	65
23	The ADAMTS1 Protease Gene Is Required for Mammary Tumor Growth and Metastasis. <i>American Journal of Pathology</i> , 2011, 179, 3075-3085.	1.9	64
24	The metalloproteinase ADAMTS1: A comprehensive review of its role in tumorigenic and metastatic pathways. <i>International Journal of Cancer</i> , 2013, 133, 2263-2276.	2.3	63
25	The Magnitude of Androgen Receptor Positivity in Breast Cancer Is Critical for Reliable Prediction of Disease Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 2328-2341.	3.2	63
26	Decreased Androgen Receptor Levels and Receptor Function in Breast Cancer Contribute to the Failure of Response to Medroxyprogesterone Acetate. <i>Cancer Research</i> , 2005, 65, 8487-8496.	0.4	58
27	Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides. <i>Clinical and Experimental Metastasis</i> , 2011, 28, 113-125.	1.7	58
28	Annexin A2 is regulated by ovarian cancer-peritoneal cell interactions and promotes metastasis. <i>Oncotarget</i> , 2013, 4, 1199-1211.	0.8	58
29	Hypoxia induced HIF-1/HIF-2 activity alters trophoblast transcriptional regulation and promotes invasion. <i>European Journal of Cell Biology</i> , 2015, 94, 589-602.	1.6	58
30	Overexpression of piRNA Pathway Genes in Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2014, 9, e99687.	1.1	54
31	Differing Roles of Hyaluronan Molecular Weight on Cancer Cell Behavior and Chemotherapy Resistance. <i>Cancers</i> , 2018, 10, 482.	1.7	54
32	Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 441-455.	1.7	50
33	Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance. <i>Oncotarget</i> , 2017, 8, 17819-17832.	0.8	44
34	Elevated levels of HER2 and androgen receptor in clinically localized prostate cancer identifies metastatic potential. <i>Prostate</i> , 2008, 68, 830-838.	1.2	43
35	Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway. <i>International Journal of Cancer</i> , 2020, 146, 2268-2280.	2.3	41
36	Aberrant Lipid Metabolism: An Emerging Diagnostic and Therapeutic Target in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2013, 14, 7742-7756.	1.8	39

#	ARTICLE	IF	CITATIONS
37	Targeting CDK9 for treatment of colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 2178-2193.	2.1	39
38	Diverse molecular pathways in ovarian cancer and their clinical significance. <i>Maturitas</i> , 2009, 62, 270-275.	1.0	38
39	Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome. <i>Translational Research</i> , 2016, 171, 83-95.e2.	2.2	37
40	Apolipoprotein-D: A novel cellular marker for HGPIN and prostate cancer. <i>Prostate</i> , 2004, 58, 103-108.	1.2	32
41	Mutant p53 upregulates alpha-1 antitrypsin expression and promotes invasion in lung cancer. <i>Oncogene</i> , 2017, 36, 4469-4480.	2.6	32
42	S100A10 and Cancer Hallmarks: Structure, Functions, and its Emerging Role in Ovarian Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4122.	1.8	32
43	Novel ex vivo ovarian cancer tissue explant assay for prediction of chemosensitivity and response to novel therapeutics. <i>Cancer Letters</i> , 2018, 421, 51-58.	3.2	31
44	Development and characterization of primary cultures of smooth muscle cells from the fibromuscular stroma of the guinea pig prostate. <i>In Vitro Cellular & Developmental Biology</i> , 1989, 25, 1016-1024.	1.0	29
45	4-Methylumbelliferone Inhibits Cancer Stem Cell Activation and Overcomes Chemoresistance in Ovarian Cancer. <i>Cancers</i> , 2019, 11, 1187.	1.7	29
46	Conservation and Expression of PIWI-Interacting RNA Pathway Genes in Male and Female Adult Gonad of Amniotes. <i>Biology of Reproduction</i> , 2013, 89, 136.	1.2	28
47	Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 10.	3.5	26
48	A simple index using video image analysis to predict disease outcome in primary breast cancer. , 1999, 84, 203-208.		25
49	Immunohistochemical Level of Unsulfated Chondroitin Disaccharides in the Cancer Stroma Is an Independent Predictor of Prostate Cancer Relapse. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 2488-2497.	1.1	24
50	IMMUNOLOCALIZATION OF APOLIPOPROTEIN D, ANDROGEN RECEPTOR AND PROSTATE SPECIFIC ANTIGEN IN EARLY STAGE PROSTATE CANCERS. <i>Journal of Urology</i> , 1998, 159, 548-554.	0.2	23
51	Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. <i>Journal of Clinical Medicine</i> , 2020, 9, 2967.	1.0	23
52	Proteoglycans: Potential Agents in Mammographic Density and the Associated Breast Cancer Risk. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2015, 20, 121-131.	1.0	21
53	WOMEN IN CANCER THEMATIC REVIEW: Ovarian cancer's peritoneal cell interactions promote extracellular matrix processing. <i>Endocrine-Related Cancer</i> , 2016, 23, T155-T168.	1.6	21
54	Androgen Receptor Protein Levels Are Significantly Reduced in Serous Ovarian Carcinomas Compared with Benign or Borderline Disease but Are Not altered by Cancer Stage or Metastatic Progression. <i>Hormones and Cancer</i> , 2013, 4, 154-164.	4.9	20

#	ARTICLE	IF	CITATIONS
55	STEROID HORMONE AND EPIDERMAL GROWTH FACTOR RECEPTORS IN MENINGIOMAS. ANZ Journal of Surgery, 1989, 59, 881-888.	0.3	18
56	Elevated levels of tumour apolipoprotein D independently predict poor outcome in breast cancer patients. Histopathology, 2020, 76, 976-987.	1.6	18
57	Expression and localization of homeodomain proteins DLX4/HB9 in normal and malignant human breast tissues. Anticancer Research, 2003, 23, 1479-88.	0.5	18
58	Effects of oestradiol-17 β and 5 α -dihydrotestosterone on guinea-pig prostate smooth muscle cell proliferation and steroid receptor expression in vitro. Journal of Endocrinology, 1994, 140, 373-383.	1.2	17
59	Suppression of Androgen Receptor Signaling in Prostate Cancer Cells by an Inhibitory Receptor Variant. Molecular Endocrinology, 2006, 20, 1009-1024.	3.7	17
60	Characterization of the prostate cancer susceptibility gene <i>KLF6</i> in human and mouse prostate cancers. Prostate, 2013, 73, 182-193.	1.2	17
61	Prostatic chondroitin sulfate is increased in patients with metastatic disease but does not predict survival outcome. Prostate, 2009, 69, 761-769.	1.2	16
62	Co-expression of the androgen receptor and the transcription factor ZNF652 is related to prostate cancer outcome. Oncology Reports, 2010, 23, 1045-52.	1.2	14
63	Comparative Biomarker Expression and RNA Integrity in Biospecimens Derived from Radical Retropubic and Robot-Assisted Laparoscopic Prostatectomies. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1755-1765.	1.1	13
64	Matrix Assisted Laser Desorption/Ionization Mass Spectrometry Imaging (MALDI MSI) for Monitoring of Drug Response in Primary Cancer Spheroids. Proteomics, 2019, 19, 1900146.	1.3	13
65	An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy. International Journal of Cancer, 2019, 144, 1151-1159.	2.3	13
66	Targeting Aquaporins in Novel Therapies for Male and Female Breast and Reproductive Cancers. Cells, 2021, 10, 215.	1.8	13
67	Reduced Gonadotrophin Receptor Expression Is Associated with a More Aggressive Ovarian Cancer Phenotype. International Journal of Molecular Sciences, 2021, 22, 71.	1.8	12
68	Changes in steroid receptors and proteoglycan expression in the guinea pig prostate stroma during puberty and hormone manipulation. Prostate, 2007, 67, 288-300.	1.2	11
69	Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer. Anticancer Research, 2019, 39, 2475-2482.	0.5	9
70	A first-in-class CDK4 inhibitor demonstrates in vitro, ex-vivo and in vivo efficacy against ovarian cancer. Gynecologic Oncology, 2020, 159, 827-838.	0.6	9
71	Effect of Selenium and Iodine on Oxidative Stress in the First Trimester Human Placenta Explants. Nutrients, 2021, 13, 800.	1.7	9
72	A Comprehensive Molecular and Clinical Analysis of the piRNA Pathway Genes in Ovarian Cancer. Cancers, 2021, 13, 4.	1.7	9

#	ARTICLE	IF	CITATIONS
73	Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery. International Journal of Molecular Sciences, 2011, 12, 410-428.	1.8	7
74	ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome. , 2021, 4, 485-502.		6
75	Small glutamine-rich tetratricopeptide repeat-containing protein alpha is present in human ovaries but may not be differentially expressed in relation to polycystic ovary syndrome. Fertility and Sterility, 2013, 99, 2076-2083.e1.	0.5	5
76	Diagnostic Value of Plasma Annexin A2 in Early-Stage High-Grade Serous Ovarian Cancer. Diagnostics, 2021, 11, 69.	1.3	5
77	ADAMTS1 Promotes Adhesion to Extracellular Matrix Proteins and Predicts Prognosis in Early Stage Breast Cancer Patients. Cellular Physiology and Biochemistry, 2019, 52, 1553-1568.	1.1	5
78	Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines. Cancers, 2022, 14, 2362.	1.7	5
79	Chemoresistant Cancer Cell Lines Are Characterized by Migratory, Amino Acid Metabolism, Protein Catabolism and IFN1 Signalling Perturbations. Cancers, 2022, 14, 2763.	1.7	4
80	Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug. International Journal of Molecular Sciences, 2021, 22, 10844.	1.8	3
81	Androgen receptor levels during progression of prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Medical Journal of Indonesia, 0, , 5.	0.2	2
82	Chick chorioallantoic membrane assay: a 3D animal model for cancer invasion and metastasis. , 2020, , 221-231.		2
83	The effect of zinc on human trophoblast proliferation and oxidative stress. Journal of Nutritional Biochemistry, 2021, 90, 108574.	1.9	2
84	WOMEN IN CANCER PROFILE: My pathway to understanding the role of the tumour microenvironment in cancer progression. Endocrine-Related Cancer, 2016, 23, P27-P31.	1.6	1
85	Abstract 5184: Real-time cytotoxicity assays as a pre-clinical screening tool for LGR5-targeting CAR-T cells for treatment of solid tumors. Cancer Research, 2022, 82, 5184-5184.	0.4	1